PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Marine-Derived Drugs in Alzheimer's: Modest, Inconsistent Cognitive Signals

GV-971sodium oligomannatetramiprosatehomotaurineomega-3 fatty acidsbryostatin-1rifampicindoxycyclineAlzheimer's diseasenetwork meta-analysiscognitive outcomesmarine-derived drugs Neurology / Neuropharmacology

Background Information

Marine-derived drugs show potential but varied cognitive effects in Alzheimer's.

Marine-derived drugs are being explored for cognitive benefits in Alzheimer's disease (AD), but comparative efficacy and safety require clarification. GV-971 improved ADAS-Cog scores (MD -1.85, 95% CI -2.89 to -0.82), and rifampicin showed potential MMSE benefits (MD 1.90, 95% CI 0.25 to 3.56), but outcomes varied. While some marine drugs show cognitive improvement in specific measures, none are consistently superior; further large RCTs are needed to determine optimal treatments. Marine-derived drugs show potential but inconsistent cognitive benefits in Alzheimer's disease.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Song Z, Xie Y, Zhu H, Li J, Yang C, Guo Y, Nong X, Zhu Z, Chen Z, Wang Z

Citation: Song Z, Xie Y, Zhu H, et al. Evaluating the cognitive efficacy of marine-derived drugs in Alzheimer's disease: A systematic review and Bayesian network meta-analysis. Therapeutic advances in neurological disorders. 2026;19:17562864261476868. doi:10.1177/17562864261476868

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.